 Rigel Pharmaceuticals, Inc. NASDAQ: RIGL shares are trading lower after the company announced data from the FORWARD Phase 3 clinical trial of Fostamatinib did not demonstrate statistical significance in the primary efficacy endpoint. Fostamatinib is currently being evaluated in a Phase 3. 